Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 1/10/21 → 30/09/24 |
Funding
- Leukemia & Lymphoma Society: A$896,406.82
Targeting DCAF1 as a novel treatment strategy for therapy resistant multiple myeloma
- Kats, Lev (Primary Chief Investigator (PCI))
- Shortt, Jake (Chief Investigator (CI))
- Thompson, Philip (Chief Investigator (CI))
- Ott, Christopher J. (Chief Investigator (CI))
Project: Research